Amgen stock rose early Wednesday, though the biotech behemoth said the FDA placed one of its obesity treatments on clinical ...

Amgen Inc. sees the potential for 2025 revenues to top Wall Street estimates thanks to growth in cholesterol and cancer drugs ...

The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

Amgen (AMGN) provided updates on selected product and pipeline programs, including that a Phase 1 study of AMG 513 in people living with ...

Americans are split on using weight loss drugs such as Ozempic and Wegovy to treat obesity or weight-related conditions, ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance. The approach is especially popular among telemedicine physicians, who ...

New poll shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs if they are ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...

The FDA says new labels will make it easier to spot harmful ingredients. A UVA nutritionist suggests taking a holistic ...